Target intelligence / Profile preview

Suppressor of cytokine signaling 2 (SOCS2)

Target
SOCS2
Molecular classification
Negative regulator of cytokine signaling, Adapter protein for E3 ubiquitin ligase, SH2 domain-containing intracellular protein
01

Overview

Suppressor of cytokine signaling 2 is a cytoplasmic adapter protein containing a central SH2 domain and a C-terminal SOCS box. It is upregulated by cytokine stimulation and negatively regulates JAK-STAT signaling either by direct inhibition or by kinase receptor degradation via ubiquitination. SOCS2 is a key feedback inhibitor controlling growth hormone/IGF-1 signaling, proliferation, and immune cell differentiation, particularly in T cells and NK cells. Pathologic perturbation of SOCS2 function can contribute to abnormal growth, cancer, immune dysfunction, and metabolic diseases. Key features include: Negative regulator of cytokine and growth hormone signaling; Interacts with insulin-like growth factor 1 receptor, erythropoietin receptor, leptin receptor, and components of the JAK-STAT pathway; Functions as substrate recognition subunit in a cullin5 E3 ubiquitin ligase complex; No currently approved direct-targeting drugs, but significant interest as a mediator for targeted protein degradation strategies.

Other names
CIS2SSI2STATI2SOCS-2CIS-2SSI-2Cish2Cytokine-inducible SH2 protein 2STAT-induced STAT inhibitor 2
02

Mechanism of action

Drugs targeting SOCS2 (experimental): PROTACs or molecular degraders use SOCS2’s SOCS box to recruit cullin5 E3 ubiquitin ligase for targeted substrate degradation

03

Biological functions

Negative feedback of JAK-STAT signalingRegulation of growth hormone and IGF-1 signalingRegulation of immune cell differentiation (T and NK cells)Control of inflammatory cytokine productionUbiquitin-mediated receptor degradation
04

Disease associations

Cancer (modulation of tumor growth and immune response)Inflammation and autoimmunityCardiovascular diseaseMetabolic disorders/insulin resistanceSevere infections/bacterial defense
05

Safety considerations

Risk of excessive immune suppression or stimulation if SOCS2 is inhibited or overexpressedPotential for abnormal growth or metabolic disturbance due to dysregulation of GH/IGF-1 signalingPossibility of impaired resolution of inflammation leading to tissue damage or infection
06

Interacting drugs

No approved drugs directly targeting SOCS2, but it is currently under investigation, including for targeted protein degradation applications (e.g. use as substrate recognition subunit in PROTACs and E3 ligase-based therapies)
07

Biomarkers

SOCS2 expression levels (potential for immune profiling and growth disorders)SOCS2 protein detection in tissue or plasma (experimental research setting)

Beyond the preview

Go deeper on Suppressor of cytokine signaling 2 (SOCS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suppressor of cytokine signaling 2 (SOCS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call